- Home
- DOMH vs ADXN Comparison
DOMH vs ADXN Comparison
Compare DOMH & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- ADXN
- Stock Information
- Founded
- DOMH 1967
- ADXN 2002
- Country
- DOMH United States
- ADXN Switzerland
- Employees
- DOMH N/A
- ADXN N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- ADXN Health Care
- Exchange
- DOMH Nasdaq
- ADXN Nasdaq
- Market Cap
- DOMH 74.9M
- ADXN 8.2M
- IPO Year
- DOMH N/A
- ADXN N/A
- Fundamental
- Price
- DOMH $5.25
- ADXN $7.10
- Analyst Decision
- DOMH
- ADXN Strong Buy
- Analyst Count
- DOMH 0
- ADXN 1
- Target Price
- DOMH N/A
- ADXN $30.00
- AVG Volume (30 Days)
- DOMH 1.5M
- ADXN 8.5K
- Earning Date
- DOMH 05-08-2025
- ADXN 03-24-2025
- Dividend Yield
- DOMH 5.93%
- ADXN N/A
- EPS Growth
- DOMH N/A
- ADXN N/A
- EPS
- DOMH N/A
- ADXN 0.06
- Revenue
- DOMH $12,589,000.00
- ADXN $701,260.00
- Revenue This Year
- DOMH N/A
- ADXN N/A
- Revenue Next Year
- DOMH N/A
- ADXN N/A
- P/E Ratio
- DOMH N/A
- ADXN $0.96
- Revenue Growth
- DOMH 1117.50
- ADXN N/A
- 52 Week Low
- DOMH $0.83
- ADXN $6.67
- 52 Week High
- DOMH $13.58
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- DOMH 44.59
- ADXN 44.29
- Support Level
- DOMH $5.18
- ADXN $6.77
- Resistance Level
- DOMH $8.55
- ADXN $8.00
- Average True Range (ATR)
- DOMH 1.30
- ADXN 0.83
- MACD
- DOMH -0.56
- ADXN -0.10
- Stochastic Oscillator
- DOMH 1.45
- ADXN 10.75
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.